Saint Herblain, France, January 30, 2025
Valneva SE Signs $32.8 Million Contract with U.S. Department of Defense
Valneva SE, a specialty vaccine company, announced today the signing of a new one-year contract worth $32.8 million with the United States Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO®.
Under this new contract, the DoD will purchase a minimum of $32.8 million worth of IXIARO® vaccines with the option to buy additional doses within the next twelve months. Deliveries of IXIARO® have been ongoing since 2024 under a previous supply contract signed in September 2023.
This latest agreement highlights the importance of vaccines in protecting public health and national security. The DoD’s continued investment in vaccines like IXIARO® showcases their commitment to safeguarding military personnel and civilian populations against infectious diseases.
Japanese encephalitis is a serious viral infection transmitted through mosquito bites, with symptoms ranging from mild flu-like illness to severe neurological complications. By supplying IXIARO®, Valneva SE is contributing to the global effort to control and eradicate this preventable disease.
How does this affect me?
As a member of the general public, the DoD’s contract with Valneva SE for the supply of IXIARO® may not have a direct impact on you. However, it demonstrates the importance of vaccine development and distribution in combatting infectious diseases, both locally and globally. The availability of vaccines like IXIARO® helps protect communities from outbreaks and ensure public health safety.
How does this affect the world?
The contract between Valneva SE and the U.S. DoD signifies a coordinated effort to address global health challenges, such as Japanese encephalitis. By investing in vaccines and securing the supply of vital immunizations, countries can work together to enhance disease prevention and control on a worldwide scale. This collaboration underscores the significance of international partnerships in promoting health security for all.
Conclusion
The $32.8 million contract between Valneva SE and the U.S. Department of Defense for IXIARO® reflects a commitment to public health and national security. By prioritizing vaccine procurement and distribution, stakeholders are taking proactive steps to protect populations from infectious diseases and strengthen global health resilience. This partnership serves as a testament to the collective efforts needed to address health challenges and promote well-being for all individuals worldwide.
